Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

slno

Total Debt

Last Annual Value

2.69M

3-Year CAGR

159%

5-Year CAGR

81%

10-Year CAGR

%

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Competitors Analysis of Total Debt

SLNO · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.69M
88.3%42.5%N/A 
1.28B
209.2%98.0%N/A
20.28M
-9.6%-9.1%-45.6%
CELC logo
Celcuity Inc.
NASDAQ:CELC
195.38M
73.4%67.3%N/A
110.00K
-64.7%-52.0%N/A
137.00K
-52.3%36.4%-27.2%
8.85M
63.2%N/AN/A
319.45M
1.2%161.5%N/A
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

Intrinsic Value
Current Price: $53.01